Re-treatment, weekly for 4 doses In a multi-centre, single-arm study, 58 patients with relapsed or chemoresistant low grade or follicular B cell NHL, who had achieved an objective clinical response to a prior course of MabThera, were re- treated with 375 mg/ m2 of MabThera as intravenous infusion weekly for four doses.
Patsiendid said kordusravina 4 nädala jooksul 375 mg/ m2 MabThera´t veeniinfusioonina üks kord nädalas.